

**American College of Radiology  
End User License Agreement**

ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: <http://www.acr.org/~media/ACR/Documents/AppCriteria/TermsandConditions.pdf>

Personal use of material is permitted for research, scientific and/or information purposes only. You may not modify or create derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology.

**American College of Radiology  
ACR Appropriateness Criteria®  
Renal Transplant Dysfunction**

**Variant 1: Renal transplant dysfunction.**

Radiologic Procedure	Rating	Comments	RRL*
US duplex Doppler kidney transplant	9	This procedure is a first-line imaging evaluation.	O
Tc-99m MAG3 scan kidney	7	This procedure is complementary to US duplex Doppler.	☼ ☼ ☼
Tc-99m DTPA scan kidney	5		☼ ☼ ☼
CT abdomen and pelvis with IV contrast	5		☼ ☼ ☼ ☼
Arteriography kidney	5	This procedure is used after noninvasive vascular assessment has been performed. It is used to confirm RAS or other vascular abnormality and guide treatment.	☼ ☼ ☼
CTA abdomen and pelvis with IV contrast	5		☼ ☼ ☼ ☼ ☼
CT abdomen and pelvis without and with IV contrast	4		☼ ☼ ☼ ☼
CT abdomen and pelvis without IV contrast	4		☼ ☼ ☼ ☼
MRI abdomen and pelvis without and with IV contrast	4		O
MRI abdomen and pelvis without IV contrast	4		O
MRA abdomen and pelvis without and with IV contrast	4		O
MRA abdomen and pelvis without IV contrast	4		O
X-ray intravenous urography	1		☼ ☼ ☼
X-ray antegrade pyelography	1		☼ ☼ ☼
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

# RENAL TRANSPLANT DYSFUNCTION

Expert Panel on Urologic Imaging: Myles T. Taffel, MD<sup>1</sup>; Paul Nikolaidis, MD<sup>2</sup>; Michael D. Beland, MD<sup>3</sup>; M. Donald Blaufox, MD, PhD<sup>4</sup>; Vikram S. Dogra, MD<sup>5</sup>; Stanley Goldfarb, MD<sup>6</sup>; John L. Gore, MD<sup>7</sup>; Howard J. Harvin, MD<sup>8</sup>; Marta E. Heilbrun, MD, MS<sup>9</sup>; Matthew T. Heller, MD<sup>10</sup>; Gaurav Khatri, MD<sup>11</sup>; Glenn M. Preminger, MD<sup>12</sup>; Andrei S. Purysko, MD<sup>13</sup>; Andrew D. Smith, MD, PhD<sup>14</sup>; Zhen J. Wang, MD<sup>15</sup>; Robert M. Weinfeld, MD<sup>16</sup>; Jade J. Wong-You-Cheong, MD<sup>17</sup>; Erick M. Remer, MD<sup>18</sup>; Mark E. Lockhart, MD, MPH.<sup>19</sup>

## **Summary of Literature Review**

### **Introduction/Background**

Renal transplantation is the preferred treatment method in patients with end-stage renal failure. Compared with maintenance dialysis, most patients who receive a successful transplant experience an improved quality of life and a significant reduction in mortality [1]. According to the Organ Procurement and Transplantation Network of the U.S. Health Resources and Services Administration, over 375,000 renal transplants have been performed in the United States since 1988 [2]. In 2014 alone, 17,108 renal transplants were performed, of which 11,570 were from deceased donors and 5538 were from living donors. Unfortunately, there remains a huge imbalance between organ availability and demand. Although the number of candidates on the waiting list has increased, the total number of renal transplants performed in the United States has not increased significantly in the last decade. When a renal transplant is performed, every effort is made to address allograft dysfunction by management of immunosuppression and transplant complications. Five-year survival rates for the graft in renal transplant patients range from 72% to 99%, with the best rates seen in patients receiving kidneys from living donors.

Although the timing of intrinsic renal dysfunction may aid in narrowing the differential diagnosis, there is significant overlap between the various etiologies. In the immediate postoperative period (<1 week), the most common etiology of intrinsic dysfunction is acute tubular necrosis (ATN). ATN is seen in the immediate post-transplant period in a high percentage of cadaver grafts but occurs infrequently in living related donors. Acute rejection occurs from 1 week to 1 month after transplantation. Fortunately, acute rejection is an uncommon occurrence in current practice [3]. Although the introduction of calcineurin inhibitors (cyclosporine and tacrolimus) has dramatically reduced the rate of acute allograft rejection, these drugs are nephrotoxic at supratherapeutic levels [4]. Toxicity is most common in the second or third month after transplantation, when the drugs are being titrated [5]. Chronic rejection is the most common cause of late graft dysfunction and presents at least 3 months following transplantation.

Like intrinsic renal dysfunction, vascular complications and peri-transplant collections are most often encountered during specific postoperative time periods. Renal artery thrombosis (RAT) and renal vein thrombosis (RVT) usually occur in the first week after transplantation. They are usually the result of technical surgical difficulties and/or clotting disorders [6]. Renal artery stenosis (RAS) is the most common vascular complication, with an incidence of 1% to 2% [6,7]. Although it can occur at any time, RAS usually presents between 3 months and 24 months following transplantation. Peri-graft collections occur in up to 50% of patients following transplantation [8]. Seromas and hematomas generally occur in the first week following surgery. Abscesses and urinomas usually occur 1 to 3 weeks after transplantation. Lymphoceles typically present 1 to 2 months after transplantation [9].

Radiology plays a critical role in the diagnosis and management of renal transplant dysfunction. Ultrasound (US) is the modality of choice to evaluate renal transplants early in the postoperative period, in the post-transplant period, and also for long-term follow-up. US is also used to guide diagnostic and therapeutic interventions, such as biopsy, nephrostomy placement, and fluid aspiration. Radionuclide imaging is a modality capable of assessing

---

<sup>1</sup>Principal Author, George Washington University Hospital, Washington, District of Columbia. <sup>2</sup>Panel Vice-chair, Northwestern University, Chicago, Illinois. <sup>3</sup>Rhode Island Hospital, Providence, Rhode Island. <sup>4</sup>Albert Einstein College of Medicine, Bronx, New York, Society of Nuclear Medicine and Molecular Imaging. <sup>5</sup>University of Rochester Medical Center, Rochester, New York. <sup>6</sup>University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, American Society of Nephrology. <sup>7</sup>University of Washington, Seattle, Washington, American Urological Association. <sup>8</sup>Scottsdale Medical Imaging, Scottsdale, Arizona. <sup>9</sup>University of Utah, Salt Lake City, Utah. <sup>10</sup>University of Pittsburgh, Pittsburgh, Pennsylvania. <sup>11</sup>UT Southwestern Medical Center, Dallas, Texas. <sup>12</sup>Duke University Medical Center, Durham, North Carolina, American Urological Association. <sup>13</sup>Cleveland Clinic, Cleveland, Ohio. <sup>14</sup>The University of Mississippi Medical Center, Jackson, Mississippi. <sup>15</sup>University of California San Francisco School of Medicine, San Francisco, California. <sup>16</sup>Oakland University William Beaumont School of Medicine, Troy, Michigan. <sup>17</sup>University of Maryland School of Medicine, Baltimore, Maryland. <sup>18</sup>Specialty Chair, Cleveland Clinic, Cleveland, Ohio. <sup>19</sup>Panel Chair, University of Alabama at Birmingham, Birmingham, Alabama.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: [publications@acr.org](mailto:publications@acr.org)

graft function both qualitatively and quantitatively [10]. Computed tomography (CT) and magnetic resonance imaging (MRI) can provide information about structural abnormalities like arterial stenosis and arterial or venous thrombosis. Angiography is used for treatment of complications like RAS, pseudoaneurysm (PSA), and arteriovenous fistula (AVF).

## Ultrasound

Since renal transplants typically are located anteriorly in the pelvis, they are usually readily examined with US. US is routinely used to evaluate the transplant within the first 24 hours after transplantation and also serves as the first-line evaluation method following the onset of transplant dysfunction. Grayscale images are obtained to evaluate for transplant size, echotexture, hydronephrosis, peri-transplant fluid collections, and masses and to measure renal cortical thickness. Color Doppler images evaluate the patency and direction of flow in transplant arteries and veins. Spectral analysis of vascular waveforms and velocities can provide information about a range of pathologies, including RAS and RVT. Advantages of US over CT include portability, no radiation exposure, and the lack of need for potentially nephrotoxic iodinated contrast agents. US is fast and real time, particularly when compared to MRI. Vascular evaluation with US instead of MRI can avoid the risk of nephrogenic systemic fibrosis (NSF) from gadolinium-based contrast agents. A relative limitation of US in comparison to CT or MRI is its operator dependence.

Grayscale US abnormalities in dysfunctional renal transplants include a reduction in corticomedullary differentiation, reduction in renal sinus echogenicity, increased and reduced renal parenchymal echoes, and increased cortical echogenicity. Unfortunately, these findings are of limited value as the features are nonspecific and generally occur well after the onset of transplant dysfunction.

Renal segmental or intralobar artery resistive indices (RI), measured by duplex Doppler US, are often used as a nonspecific parameter for allograft dysfunction. Although RI values differ between normal and abnormal allografts, studies have suggested that the RI is neither sensitive nor specific in identifying the cause of functional transplant dysfunction [11,12]. Using RI  $>0.90$  in 145 examinations of 81 patients, Rifkin et al [13] found a sensitivity of 13%, a specificity of 100%, a positive predictive value (PPV) of 100%, and a negative predictive value (NPV) of 66% in making the diagnosis of acute rejection with duplex Doppler US. Genkins et al [14] found a sensitivity of 9%, a specificity of 91%, a PPV of 29%, and an NPV of 70% using an RI cutoff of 0.90 for the diagnosis of allograft rejection. Previous studies have shown that renal arterial RI is useful in predicting graft survival [15], especially when using a lower RI cutoff of 0.8. Radermacher et al [15], using a cutoff of 0.80 at 3 months after transplantation, found that 47% of patients with RI  $>0.80$  developed chronic allograft nephropathy (CAN), compared to 9% of patients with RI  $<0.80$ . McArthur et al [16] found that both RI and pulsatility index measured between week 1 and 3 months significantly correlated with the 1-year estimated glomerular filtration rate.

Although an RI  $>0.80$  was initially thought to correlate with allograft dysfunction, a recent study by Naesens et al [17] raises doubt on this theory. Their single-center prospective study analyzed RI at the time of protocol-specified renal allograft biopsies in addition to patients with graft dysfunction. Patients with RI  $>0.80$  did have 4.12 times higher mortality at 24 months than those  $<0.80$ , but their need for dialysis did not differ. The RI was significantly higher at the time of biopsy performed in patients with graft dysfunction, but changes in the RI did not reflect changes in histologic features when biopsies were performed at protocol-specific time points. The authors surmised that these changes did not reflect an underlying intrarenal disease process but were related to patient age and central hemodynamic factors. This complex interaction of coexisting factors in renal transplants makes the interpretation of Doppler parameters difficult. Despite this recent study, US with Doppler imaging remains the first-line imaging in the early post-transplantation period as it establishes a baseline for future comparisons.

Doppler US is a first-line noninvasive tool in the evaluation of suspected RAS and uses a combination of direct insonation of the anastomosis and main renal artery in addition to indirect intrarenal waveform morphology. Peak systolic velocity (PSV) in the renal artery is commonly used as the parameter to assess for the presence of RAS on US. Cutoff values of 200 to 300 cm/s have been proposed in various studies [18,19], but the lower limit suffers from low specificity, leading to unnecessary angiography procedures [20]. As in native kidneys, a tardus parvus waveform (small peak amplitude with delayed upstroke) can be seen within the transplanted kidney downstream to the stenosis. This morphologic waveform change is reflected quantitatively by the acceleration time (AT). De Moraes et al [21] reported a sensitivity of 90% to 96.8% and a specificity of 87.5% to 70% using various PSV thresholds in the main renal artery and a sensitivity of 100% and specificity of 96.7% using an AT of 0.09 or less as normal. Another parameter that can be used is the renal artery to iliac artery ratio, which has been shown to

have a sensitivity of 90% and specificity of 96.7% using a cutoff value of 1.8. Alternatively, AbuRahma et al [22] found that a PSV of 285 cm/s or renal-aortic ratio of 3.7 alone was better than any combination of PSVs, end-diastolic velocities, or renal-aortic ratios in detecting  $\geq 60\%$  stenosis. As evaluation for RAS with US is operator dependent, MR angiography (MRA) or CT angiography (CTA) may be more reliable in centers with little experience in evaluating for RAS with US.

The US appearance of RAT is striking, with complete absence of flow in the renal vessels on color flow and spectral analysis. Power Doppler imaging may be helpful because of its capability to detect low flow. However, it is important to remember that the absence of arterial flow within the kidney can also be seen in patients with hyperacute rejection and RVT [23]. Absence of renal venous flow and renal enlargement are classically seen in patients with RVT. Reversal of flow in the renal artery in diastole is often found in association with RVT [24]; however, this represents only approximately 10% of cases of reversed diastolic flow. Reversal of flow is seen more commonly in rejection or ATN and occasionally with nephrosclerosis [25].

US is also a useful tool in the detection of PSAs and AVFs, which may occur after biopsy. Although these complications resolve spontaneously in most cases, they can affect allograft function if they are large. PSAs may appear as a simple or minimally complex cyst on B-mode US. On color Doppler, a “yin-yang” flow pattern is usually seen within the body of the pseudoaneurysm. The spectral Doppler appearance of to-and-fro flow is detected in the neck of the pseudoaneurysm. Although often treated with endovascular technique, anatomically suitable PSAs can be treated with US-guided percutaneous thrombin injection [26]. While often detectable on B-mode US, AVFs demonstrate a focal mosaic appearance on color Doppler secondary to tissue reverberation. On spectral Doppler, the feeding artery demonstrates a high-velocity, low-resistance waveform, and the draining vein waveform may be pulsatile or “arterialized.”

Postoperative fluid collections like abscess, hematoma, lymphocele, and urinoma can be identified on US, but it cannot reliably differentiate between them. Sometimes an US examination may not demonstrate the extent of the collection and a noncontrast CT may be required. If large, these collections can lead to hydronephrosis; compression of the renal vein, leading to RVT; or compression of femoral vessels, leading to lower-extremity swelling or deep venous thrombosis. Large hematomas may lead to Page kidney. The time frame in which the collection is discovered has some prognostic ability since urinomas, hematomas, and abscesses occur in the early postoperative period, whereas lymphoceles occur weeks to months after surgery. Lymphoceles more often have septa than other collections, and hematomas tend to have higher echogenicity. In order to differentiate these entities, aspiration is usually required, and this is commonly performed with US guidance. Hydronephrosis can also be easily identified with US; however, it should be interpreted in correlation with biochemical data since reflux can give a similar appearance as well [27]. Urine leak may appear as a fluid collection on US, but an isotope scan would be more helpful [23]. Leaks are definitively diagnosed by aspiration of the collection with measurement of creatinine.

Since ATN and acute rejection cannot be diagnosed with US and serum creatinine is insensitive for detecting early graft pathology, US-guided biopsy is the standard method for the diagnosis of rejection and evaluation of immunosuppression. The complication rate from renal transplant biopsies is low, with a reported rate of 0.4% to 1% graft loss in approximately 2500 biopsies [28].

Contrast-enhanced US (CEUS) has been used by some investigators to evaluate graft perfusion both in large arteries and within the cortex. Schwenger et al [29] found that patients with CAN had significantly lower blood flow values quantified by CEUS compared to patients without CAN. In a small series, CEUS was found to be helpful in differentiating the underlying causes of delayed graft dysfunction [30]. CEUS can confirm transplant RAS and also aids in the assessment of the degree of stenosis [31]. Currently, CEUS has not received approval by the U.S. Food and Drug Administration.

US-based elastography is another tool that may aid in the noninvasive assessment of CAN. The parenchymal stiffness measured by the transient elastography technique correlates with underlying histologic interstitial fibrosis [32]. Unfortunately, kidney stiffness is not just related to the degree of fibrosis but is also related to functional and mechanical parameters [33]. Although this new tool has promise, further validation is needed in clinical practice.

### **Computed Tomography and Computed Tomography Angiography**

The utilization of CT of the abdomen and pelvis with contrast should be considered in conjunction with the risks of nephrotoxicity from iodinated contrast [34]. It may be beneficial in evaluating renal masses, perinephric fluid collections, and post-transplant lymphoproliferative disease.

In patients with suspected vascular complications (RAS, RVT, PSA, AVF), CTA can provide a detailed anatomic depiction prior to undergoing percutaneous angiography. Data about the usefulness of CT in evaluating transplant vascular complications are limited. Helck et al [35] found abnormalities on CT in 42% of cases when US was unremarkable. These included renal infarction, renal vein stenosis, and AVF. Rountas et al [36], in their study of native kidney vasculature, found that CTA and MRA have comparable negative predictive accuracy in evaluating suspected RAS. They found that CTA had 94% sensitivity, 93% specificity, 71% PPV, and 99% NPV. A small series by Gaddikeri et al [37] that compared CTA and MRA in the assessment of transplant RAS also demonstrated little difference between the modalities. CTA, however, has the drawback of potential postcontrast acute kidney injury and radiation exposure in addition to insensitivity to mild RAS [38].

A noncontrast CT of the abdomen and pelvis may be helpful in patients with suspected hemorrhage or in the evaluation for nephrolithiasis in the transplant kidney. It also may be useful to define the extent of a peri-transplant fluid collection or in patients who cannot receive intravenous contrast.

### **Magnetic Resonance Imaging and Magnetic Resonance Angiography**

MRI is being increasingly used as a second-line imaging modality for the evaluation of kidney transplants. Like a CT with and without contrast, an MRI with and without contrast may aid in characterization of renal masses and perinephric fluid collections. Although the risk of nephrotoxicity following gadolinium chelate contrast administration remains controversial [39], there is increased risk for NSF in this patient population that often has compromised renal function [34,40]. Fortunately, nonenhanced MRI pulse sequences may provide useful information in patients that have contrast contraindications and serve as an alternative to CT.

Although digital subtraction angiography remains the reference standard for the anatomic delineation of the renal arteries, MRA permits a noninvasive method to evaluate for RAS and does not expose the patient to ionizing radiation [41]. Although MRA protocols may not provide the same parenchymal anatomic detail as a conventional MRI, MRA plays a critical role in the management of patients with transplant dysfunction. Omary et al [42] found that MRA resulted in a change in the referring clinician's initial diagnostic impression in approximately 65% of patients. In 35% of patients, angiography was avoided. Sharafuddin et al [43] studied both native and transplant renal arteries and found that preprocedural planning with the use of gadolinium-enhanced MRA significantly reduced the iodinated contrast material requirement during percutaneous renal artery interventions, in addition to shortening the procedure duration. Rountas et al [36], in studies evaluating the efficacy for native kidney RAS, found that MRA had a sensitivity of 90%, a specificity of 94%, a PPV of 75%, and an NPV of 98%. In a similar study, Law et al [44] reported a sensitivity of 97%, a specificity of 67%, a PPV of 90%, and an NPV of 86% for diagnosing native RAS.

Unfortunately, MRA suffers from a few pitfalls that may lead to a false diagnosis of stenosis or an overestimation of a stenosis. These include artifacts caused by metallic surgical clips near the transplant artery that result in signal loss near the artery, giving the false impression of stenosis. Venous contamination due to inaccurate timing of the arterial bolus is another artifact that can affect the accuracy of diagnosis. Careful evaluation of the source images and multiplanar reformats will help solve these problems [45]. In addition to depicting areas of stenosis in the main renal artery, MRA is able to depict areas of infarction within the kidney, which are seen as areas of heterogeneous T1 and T2 signal intensity and as focal areas of nonenhancement on the postcontrast images. Using 3D gadolinium-enhanced MRA for the detection of transplant RAS, Ismaeel et al [46] showed a sensitivity of 93.7%, a specificity of 80%, and an accuracy of 88.5%. In addition, outer cortical necrosis, cortical necrosis with large patches, diffuse cortical necrosis, and both cortical and medullary necrosis were visualized [47]. The loss of corticomedullary differentiation has been described in post-transplant patients with cyclosporine toxicity, rejection, and ATN [12,48,49].

Noncontrast MRA (NC-MRA) with steady-state free precession imaging can help avoid contrast utilization and avoid the risk of NSF [50]. Several studies have evaluated the value of NC-MRA in the evaluation of native RAS [51-57]. In these studies, NC-MRA of renal arteries demonstrated a sensitivity of 78% to 100%, a specificity of 82% to 99%, and an NPV of 95% to 100% in the detection of significant arterial stenosis (>50%). The PPV (57% to 92%) was lower than other parameters. The high NPV suggests that NC-MRA can be used as a screening tool for detecting RAS. When positive, other imaging modalities can be utilized for confirmation and to better assess the degree of stenosis [51]. Although technically more challenging and requiring a longer examination time, 2 small studies suggested that NC-MRA was capable of detecting transplant RAS with a similar accuracy to gadolinium-enhanced MRA [50,58].

Newer MRI techniques such as diffusion-weighted MRI (DWI-MRI) and blood oxygen level–dependent (BOLD) imaging have shown considerable promise as noninvasive techniques to detect functional changes in kidneys [59]. BOLD imaging depends on contrast generated by changing levels of paramagnetic deoxyhemoglobin with a decrease in intrarenal T2 signal during hypoxia, taken as a reflection of increasing concentrations of deoxyhemoglobin. BOLD imaging can noninvasively detect changes in intrarenal oxygenation. This technique may be useful in the differentiation of acute rejection from ATN [60-62] and to identify the hypoxia induced by RAS [63]. DWI-MRI is based on the thermally induced Brownian motion of water molecules in tissue. The quantitative apparent diffusion coefficient derived from this sequence provides information on the diffusion properties of the tissue evaluated. This technique has demonstrated promise as an indicator of allograft dysfunction [64]. A recent study suggests that although these techniques may prove useful in the assessment of function, they are limited in the characterization of the underlying cause [65]. The addition of diffusion tensor imaging to DWI may increase the sensitivity in detecting pathologic changes in renal transplants [66]. Further investigation is needed to validate the diagnostic value of these techniques in detecting allograft dysfunction.

### **X-ray Intravenous Urography and Pyelography**

X-ray intravenous urography and pyelography are no longer used for evaluation of the renal transplant.

### **Nuclear Medicine**

Radionuclide tests are valuable in renal transplantation since they provide a noninvasive means to evaluate transplant function qualitatively and also screen for surgical complications. Only scintigraphic studies are able to separate function of the graft from residual function of the native kidneys or any remaining prior failed graft [3]. Renal scintigraphy assesses the 3 sequential phases of renal function. For the first minute following tracer injection, rapid dynamic imaging evaluates perfusion. The nephrons extract the tracer from the blood and excrete it by glomerular filtration and/or tubular secretion in the second phase. In the third phase, the tracer drainage allows assessment of urinary flow [67].

Although the use of radionuclide renal imaging during the early post-transplantation period has decreased, there are still centers that routinely perform them prior to patient discharge from the hospital to serve as a baseline study for future comparison. An advantage of renography is that it provides functional information, whereas blood creatinine levels lag behind function and radiographic studies are primarily anatomic. Because of this, it can be helpful in evaluating the return of function after ATN or rejection.

Yazici et al [68] found scintigraphy performed within 2 days of transplantation was superior to RI in predicting long-term graft function. Heaf et al [69] found that a renogram performed 1 to 2 days after transplantation could predict primary graft nonfunction, prolonged time to graft function, low hospital discharge chromium EDTA clearance, and low 1- and 5-year graft survival, whereas a renogram performed at discharge could predict late (>6 months) graft loss.

Although sensitive in the detection of graft dysfunction, scintigraphic parameters do not yield sufficient diagnostic power for a specific diagnosis. Like RI, renogram changes do not contribute to the differential diagnosis between acute rejection, ATN, and cyclosporine toxicity [69,70].

RAS appears similar to the scintigraphic findings seen with rejection. Angiotensin-converting enzyme inhibitor renography can aid in the diagnosis if baseline studies are available for comparison. In obstruction, scintigraphy can be used in conjunction with furosemide, as it is in native kidneys. Urinary leaks can be identified by the presence of radioactivity in an abnormal location. In some centers and especially in Europe, renal clearances are performed serially to evaluate renal function. These are performed less frequently in the United States.

Numerous quantitative indexes are used to evaluate transplants. Although no single parameter has achieved acceptance, it appears that they may be useful. Tc-99m diethylenetriamine pentaacetic acid (DTPA) or Tc-99m mercaptoacetyl triglycine (MAG3) can be used to follow the transplant. Because of its higher extraction fraction and better image quality, MAG3 is preferred at most transplant centers. DTPA, which is not excreted, is limited in the evaluation for obstruction, only demonstrating early impact on glomerular filtration. In a limited number of studies, MAG3 has not been proven superior to DTPA [67].

### **Angiography**

RAS is reported to occur in 1% to 23% of patients following transplantation and accounts for 1% to 5% of renal transplant hypertension [26,71,72]. Percutaneous therapeutic angioplasty (PTA) and stenting (PTAS) is the treatment of choice for RAS, with a success rate of 65% to 100% [73-84]. The complication rate from PTA and PTAS of 0% to 10% is low compared to surgery, which has a graft loss rate of 15% and mortality rate of 5%.

However, in 1 long-term study over a 24-year period, Peregrin et al [80] found a higher complication rate of 25.5% (usually without clinical sequelae). The majority of these complications were related to arterial access.

In a study of 44 patients by Ghazanfar et al [76], the technical success rate of PTA was 100% and the 5-year graft survival rate was 86%. The restenosis rate after PTA has been reported to be between 10% and 56% [85]. Pappas et al [79] found a technical success rate of 100% with no acute complications, amelioration of arterial hypertension, and improvement of graft function within 7 postoperative days following PTAS. In the follow-up period, 81.8% of their patients had normal blood pressure and creatinine levels, suggesting that PTA was effective. PTAS restenosis rates are even lower than PTA at between 5% and 30% [26]. Studies comparing PTA and PTAS are sparse. Although off-label utilization of drug-eluting stents has been used to treat RAS [86-88], larger studies are needed to prove them advantageous over bare metal stents.

The treatment of PSAs is indicated if the patient is symptomatic, the aneurysm diameter is >2.5 cm, expansion is noted on repeat imaging, or the etiology is infectious. Endovascular treatment is performed with coil embolization or stent grafting [26].

AVFs are almost always iatrogenic, usually occurring following a graft biopsy. Although most resolve spontaneously, superselective embolization is highly effective, with minimal loss of renal parenchyma when needed [89,90].

### Summary of Recommendations

- US duplex Doppler is the first-line imaging evaluation method to assess the presence and causes of renal transplant dysfunction.
- Renal scintigraphy using MAG3 serves a complementary role by quantitatively assessing the 3 sequential phases of renal transplant function.
- Although US, CTA, and MRA can noninvasively diagnose RAS, angiography remains the diagnostic reference standard and is utilized to guide intervention.

### Summary of Evidence

Of the 90 references cited in the *ACR Appropriateness Criteria® Renal Transplant Dysfunction* document, 67 are categorized as diagnostic references, including 2 well-designed studies, 23 good-quality studies, and 21 quality studies that may have design limitations. Additionally, 23 references are categorized as therapeutic references, including 15 good-quality studies and 1 quality study that may have design limitations. There are 28 references that may not be useful as primary evidence.

The 90 references cited in the *ACR Appropriateness Criteria® Renal Transplant Dysfunction* document were published from 1986 to 2015.

Although there are references that report on studies with design limitations, 40 well-designed or good-quality studies provide good evidence.

### Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the *ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#)* document.



Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊛	<0.1 mSv	<0.03 mSv
⊛ ⊛	0.1-1 mSv	0.03-0.3 mSv
⊛ ⊛ ⊛	1-10 mSv	0.3-3 mSv
⊛ ⊛ ⊛ ⊛	10-30 mSv	3-10 mSv
⊛ ⊛ ⊛ ⊛ ⊛	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.		

### Supporting Documents

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

### References

1. Elsayes KM, Menias CO, Willatt J, Azar S, Harvin HJ, Platt JF. Imaging of renal transplant: utility and spectrum of diagnostic findings. *Curr Probl Diagn Radiol*. 2011;40(3):127-139.
2. OPTN/SRTR: Transplant Data 1988-2015. Available at: <http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp>.
3. Dubovsky EV, Russell CD, Erbas B. Radionuclide evaluation of renal transplants. *Semin Nucl Med*. 1995;25(1):49-59.
4. Sharfuddin A. Imaging evaluation of kidney transplant recipients. *Semin Nephrol*. 2011;31(3):259-271.
5. Zarzour JG, Lockhart ME. Ultrasonography of the Renal Transplant. *Ultrasound Clinics*. 2014;9(4):683-695.
6. Dimitroulis D, Bokos J, Zavos G, et al. Vascular complications in renal transplantation: a single-center experience in 1367 renal transplantations and review of the literature. *Transplant Proc*. 2009;41(5):1609-1614.
7. Eufrazio P, Parada B, Moreira P, et al. Surgical complications in 2000 renal transplants. *Transplant Proc*. 2011;43(1):142-144.
8. Akbar SA, Jafri SZ, Amendola MA, Madrazo BL, Salem R, Bis KG. Complications of renal transplantation. *Radiographics*. 2005;25(5):1335-1356.
9. Sharfuddin A. Renal relevant radiology: imaging in kidney transplantation. *Clin J Am Soc Nephrol*. 2014;9(2):416-429.
10. Brown ED, Chen MY, Wolfman NT, Ott DJ, Watson NE, Jr. Complications of renal transplantation: evaluation with US and radionuclide imaging. *Radiographics*. 2000;20(3):607-622.
11. Buckley AR, Cooperberg PL, Reeve CE, Magil AB. The distinction between acute renal transplant rejection and cyclosporine nephrotoxicity: value of duplex sonography. *AJR Am J Roentgenol*. 1987;149(3):521-525.
12. Steinberg HV, Nelson RC, Murphy FB, et al. Renal allograft rejection: evaluation by Doppler US and MR imaging. *Radiology*. 1987;162(2):337-342.
13. Rifkin MD, Needleman L, Pasto ME, et al. Evaluation of renal transplant rejection by duplex Doppler examination: value of the resistive index. *AJR Am J Roentgenol*. 1987;148(4):759-762.
14. Genkins SM, Sanfilippo FP, Carroll BA. Duplex Doppler sonography of renal transplants: lack of sensitivity and specificity in establishing pathologic diagnosis. *AJR Am J Roentgenol*. 1989;152(3):535-539.
15. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. *N Engl J Med*. 2003;349(2):115-124.
16. McArthur C, Geddes CC, Baxter GM. Early measurement of pulsatility and resistive indexes: correlation with long-term renal transplant function. *Radiology*. 2011;259(1):278-285.
17. Naesens M, Heylen L, Lerut E, et al. Intrarenal resistive index after renal transplantation. *N Engl J Med*. 2013;369(19):1797-1806.

18. Baxter GM, Ireland H, Moss JG, et al. Colour Doppler ultrasound in renal transplant artery stenosis: which Doppler index? *Clin Radiol*. 1995;50(9):618-622.
19. Krumme B, Grotz W, Kirste G, Schollmeyer P, Rump LC. Determinants of intrarenal Doppler indices in stable renal allografts. *J Am Soc Nephrol*. 1997;8(5):813-816.
20. Patel U, Khaw KK, Hughes NC. Doppler ultrasound for detection of renal transplant artery stenosis-threshold peak systolic velocity needs to be higher in a low-risk or surveillance population. *Clin Radiol*. 2003;58(10):772-777.
21. de Moraes RH, Muglia VF, Mamere AE, et al. Duplex Doppler sonography of transplant renal artery stenosis. *J Clin Ultrasound*. 2003;31(3):135-141.
22. AbuRahma AF, Srivastava M, Mousa AY, et al. Critical analysis of renal duplex ultrasound parameters in detecting significant renal artery stenosis. *J Vasc Surg*. 2012;56(4):1052-1059, 1060 e1051; discussion 1059-1060.
23. Baxter GM. Imaging in renal transplantation. *Ultrasound Q*. 2003;19(3):123-138.
24. Baxter GM, Morley P, Dall B. Acute renal vein thrombosis in renal allografts: new Doppler ultrasonic findings. *Clin Radiol*. 1991;43(2):125-127.
25. Lockhart ME, Wells CG, Morgan DE, Fineberg NS, Robbin ML. Reversed diastolic flow in the renal transplant: perioperative implications versus transplants older than 1 month. *AJR Am J Roentgenol*. 2008;190(3):650-655.
26. Glebova NO, Brooke BS, Desai NM, Lum YW. Endovascular interventions for managing vascular complication of renal transplantation. *Semin Vasc Surg*. 2013;26(4):205-212.
27. Kashi SH, Lodge JP, Giles GR, Irving HC. Ultrasonography of renal allografts: collecting system dilatation and its clinical significance. *Nephrol Dial Transplant*. 1991;6(5):358-362.
28. Furness PN, Philpott CM, Chorbajian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. *Transplantation*. 2003;76(6):969-973.
29. Schwenger V, Hinkel UP, Nahm AM, Morath C, Zeier M. Real-time contrast-enhanced sonography in renal transplant recipients. *Clin Transplant*. 2006;20 Suppl 17:51-54.
30. Grzelak P, Szymczyk K, Strzelczyk J, et al. Perfusion of kidney graft pyramids and cortex in contrast-enhanced ultrasonography in the determination of the cause of delayed graft function. *Ann Transplant*. 2011;16(1):48-53.
31. Grzelak P, Kurnatowska I, Nowicki M, et al. Detection of transplant renal artery stenosis in the early postoperative period with analysis of parenchymal perfusion with ultrasound contrast agent. *Ann Transplant*. 2013;18:187-194.
32. Sommerer C, Scharf M, Seitz C, et al. Assessment of renal allograft fibrosis by transient elastography. *Transpl Int*. 2013;26(5):545-551.
33. Grenier N, Gennisson JL, Cornelis F, Le Bras Y, Couzi L. Renal ultrasound elastography. *Diagn Interv Imaging*. 2013;94(5):545-550.
34. American College of Radiology. *Manual on Contrast Media*. Available at: <http://www.acr.org/Quality-Safety/Resources/Contrast-Manual>.
35. Helck A, Bamberg F, Sommer WH, et al. Optimized contrast volume for dynamic CT angiography in renal transplant patients using a multiphase CT protocol. *Eur J Radiol*. 2011;80(3):692-698.
36. Rountas C, Vlychou M, Vassiou K, et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital subtraction angiography. *Ren Fail*. 2007;29(3):295-302.
37. Gaddikeri S, Mitsumori L, Vaidya S, Hippe DS, Bhargava P, Dighe MK. Comparing the diagnostic accuracy of contrast-enhanced computed tomographic angiography and gadolinium-enhanced magnetic resonance angiography for the assessment of hemodynamically significant transplant renal artery stenosis. *Curr Probl Diagn Radiol*. 2014;43(4):162-168.
38. Paven G, Waugh R, Nicholson J, Gillin A, Hennessy A. Screening tests for renal artery stenosis: a case-series from an Australian tertiary referral centre. *Nephrology (Carlton)*. 2006;11(1):68-72.
39. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. *Radiology*. 2009;250(3):618-628.
40. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR Am J Roentgenol*. 2007;188(2):586-592.
41. Prince MR, Schoenberg SO, Ward JS, Londy FJ, Wakefield TW, Stanley JC. Hemodynamically significant atherosclerotic renal artery stenosis: MR angiographic features. *Radiology*. 1997;205(1):128-136.
42. Omary RA, Baden JG, Becker BN, Odorico JS, Grist TM. Impact of MR angiography on the diagnosis and management of renal transplant dysfunction. *J Vasc Interv Radiol*. 2000;11(8):991-996.

43. Sharafuddin MJ, Stolpen AH, Dixon BS, Andresen KJ, Sun S, Lawton WJ. Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement. *J Vasc Interv Radiol*. 2002;13(9 Pt 1):901-908.
44. Law YM, Tay KH, Gan YU, Cheah FK, Tan BS. Gadolinium-enhanced magnetic resonance angiography in renal artery stenosis: comparison with digital subtraction angiography. *Hong Kong Med J*. 2008;14(2):136-141.
45. Neimatallah MA, Dong Q, Schoenberg SO, Cho KJ, Prince MR. Magnetic resonance imaging in renal transplantation. *J Magn Reson Imaging*. 1999;10(3):357-368.
46. Ismaeel MM, Abdel-Hamid A. Role of high resolution contrast-enhanced magnetic resonance angiography (HR CeMRA) in management of arterial complications of the renal transplant. *Eur J Radiol*. 2011;79(2):e122-127.
47. Helenon O, Atflan E, Legendre C, et al. Gd-DOTA-enhanced MR imaging and color Doppler US of renal allograft necrosis. *Radiographics*. 1992;12(1):21-33.
48. Hricak H, Terrier F, Demas BE. Renal allografts: evaluation by MR imaging. *Radiology*. 1986;159(2):435-441.
49. Rholl KS, Lee JK, Ling D, Sicard GA, Griffith RC, Freeman M. Acute renal rejection versus acute tubular necrosis in a canine model: MR evaluation. *Radiology*. 1986;160(1):113-117.
50. Liu X, Berg N, Sheehan J, et al. Renal transplant: nonenhanced renal MR angiography with magnetization-prepared steady-state free precession. *Radiology*. 2009;251(2):535-542.
51. Braidy C, Daou I, Diop AD, et al. Unenhanced MR angiography of renal arteries: 51 patients. *AJR Am J Roentgenol*. 2012;199(5):W629-637.
52. Glockner JF, Takahashi N, Kawashima A, et al. Non-contrast renal artery MRA using an inflow inversion recovery steady state free precession technique (Inhance): comparison with 3D contrast-enhanced MRA. *J Magn Reson Imaging*. 2010;31(6):1411-1418.
53. Maki JH, Wilson GJ, Eubank WB, Glickerman DJ, Millan JA, Hoogeveen RM. Navigator-gated MR angiography of the renal arteries: a potential screening tool for renal artery stenosis. *AJR Am J Roentgenol*. 2007;188(6):W540-546.
54. Mohrs OK, Petersen SE, Schulze T, et al. High-resolution 3D unenhanced ECG-gated respiratory-navigated MR angiography of the renal arteries: comparison with contrast-enhanced MR angiography. *AJR Am J Roentgenol*. 2010;195(6):1423-1428.
55. Utsunomiya D, Miyazaki M, Nomitsu Y, et al. Clinical role of non-contrast magnetic resonance angiography for evaluation of renal artery stenosis. *Circ J*. 2008;72(10):1627-1630.
56. Wyttenbach R, Braghetti A, Wyss M, et al. Renal artery assessment with nonenhanced steady-state free precession versus contrast-enhanced MR angiography. *Radiology*. 2007;245(1):186-195.
57. Xu JL, Shi DP, Li YL, Zhang JL, Zhu SC, Shen H. Non-enhanced MR angiography of renal artery using inflow-sensitive inversion recovery pulse sequence: a prospective comparison with enhanced CT angiography. *Eur J Radiol*. 2011;80(2):e57-63.
58. Lanzman RS, Voiculescu A, Walther C, et al. ECG-gated nonenhanced 3D steady-state free precession MR angiography in assessment of transplant renal arteries: comparison with DSA. *Radiology*. 2009;252(3):914-921.
59. Vermathen P, Binser T, Boesch C, Eisenberger U, Thoeny HC. Three-year follow-up of human transplanted kidneys by diffusion-weighted MRI and blood oxygenation level-dependent imaging. *J Magn Reson Imaging*. 2012;35(5):1133-1138.
60. Han F, Xiao W, Xu Y, et al. The significance of BOLD MRI in differentiation between renal transplant rejection and acute tubular necrosis. *Nephrol Dial Transplant*. 2008;23(8):2666-2672.
61. Sadowski EA, Djamali A, Wentland AL, et al. Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneys. *Magn Reson Imaging*. 2010;28(1):56-64.
62. Sadowski EA, Fain SB, Alford SK, et al. Assessment of acute renal transplant rejection with blood oxygen level-dependent MR imaging: initial experience. *Radiology*. 2005;236(3):911-919.
63. Juillard L, Lerman LO, Kruger DG, et al. Blood oxygen level-dependent measurement of acute intra-renal ischemia. *Kidney Int*. 2004;65(3):944-950.
64. Eisenberger U, Binser T, Thoeny HC, Boesch C, Frey FJ, Vermathen P. Living renal allograft transplantation: diffusion-weighted MR imaging in longitudinal follow-up of the donated and the remaining kidney. *Radiology*. 2014;270(3):800-808.

65. Park SY, Kim CK, Park BK, Kim SJ, Lee S, Huh W. Assessment of early renal allograft dysfunction with blood oxygenation level-dependent MRI and diffusion-weighted imaging. *Eur J Radiol.* 2014;83(12):2114-2121.
66. Lanzman RS, Ljimini A, Pentang G, et al. Kidney transplant: functional assessment with diffusion-tensor MR imaging at 3T. *Radiology.* 2013;266(1):218-225.
67. Aktas A. Transplanted kidney function evaluation. *Semin Nucl Med.* 2014;44(2):129-145.
68. Yazici B, Oral A, Gokalp C, et al. Evaluation of Renal Transplant Scintigraphy and Resistance Index Performed Within 2 Days After Transplantation in Predicting Long-Term Graft Function. *Clin Nucl Med.* 2015;40(7):548-552.
69. Heaf JG, Iversen J. Uses and limitations of renal scintigraphy in renal transplantation monitoring. *Eur J Nucl Med.* 2000;27(7):871-879.
70. Yazici B, Yazici A, Oral A, Akgun A, Toz H. Comparison of renal transplant scintigraphy with renal resistance index for prediction of early graft dysfunction and evaluation of acute tubular necrosis and acute rejection. *Clin Nucl Med.* 2013;38(12):931-935.
71. Marini M, Fernandez-Rivera C, Cao I, et al. Treatment of transplant renal artery stenosis by percutaneous transluminal angioplasty and/or stenting: study in 63 patients in a single institution. *Transplant Proc.* 2011;43(6):2205-2207.
72. Sharma S, Potdar A, Kulkarni A. Percutaneous transluminal renal stenting for transplant renal artery stenosis. *Catheter Cardiovasc Interv.* 2011;77(2):287-293.
73. Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. *Am J Transplant.* 2006;6(1):95-99.
74. Beecroft JR, Rajan DK, Clark TW, Robinette M, Stavropoulos SW. Transplant renal artery stenosis: outcome after percutaneous intervention. *J Vasc Interv Radiol.* 2004;15(12):1407-1413.
75. Geddes CC, McManus SK, Koteeswaran S, Baxter GM. Long-term outcome of transplant renal artery stenosis managed conservatively or by radiological intervention. *Clin Transplant.* 2008;22(5):572-578.
76. Ghazanfar A, Tavakoli A, Augustine T, Pararajasingam R, Riad H, Chalmers N. Management of transplant renal artery stenosis and its impact on long-term allograft survival: a single-centre experience. *Nephrol Dial Transplant.* 2011;26(1):336-343.
77. Hagen G, Wadstrom J, Magnusson M, Magnusson A. Outcome after percutaneous transluminal angioplasty of arterial stenosis in renal transplant patients. *Acta Radiol.* 2009;50(3):270-275.
78. Henning BF, Kuchlbauer S, Boger CA, et al. Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis. *Clin Nephrol.* 2009;71(5):543-549.
79. Pappas P, Zavos G, Kaza S, et al. Angioplasty and stenting of arterial stenosis affecting renal transplant function. *Transplant Proc.* 2008;40(5):1391-1396.
80. Peregrin JH, Stribrna J, Lacha J, Skibova J. Long-term follow-up of renal transplant patients with renal artery stenosis treated by percutaneous angioplasty. *Eur J Radiol.* 2008;66(3):512-518.
81. Polak WG, Jezior D, Garcarek J, et al. Incidence and outcome of transplant renal artery stenosis: single center experience. *Transplant Proc.* 2006;38(1):131-132.
82. Seratnaehai A, Shah A, Bodiwala K, Mukherjee D. Management of transplant renal artery stenosis. *Angiology.* 2011;62(3):219-224.
83. Valpreda S, Messina M, Rabbia C. Stenting of transplant renal artery stenosis: outcome in a single center study. *J Cardiovasc Surg (Torino).* 2008;49(5):565-570.
84. Voiculescu A, Schmitz M, Hollenbeck M, et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. *Am J Transplant.* 2005;5(7):1731-1738.
85. Touma J, Costanzo A, Boura B, Alomran F, Combes M. Endovascular management of transplant renal artery stenosis. *J Vasc Surg.* 2014;59(4):1058-1065.
86. Abate MT, Kaur J, Suh H, Darras F, Mani A, Nord EP. The use of drug-eluting stents in the management of transplant renal artery stenosis. *Am J Transplant.* 2011;11(10):2235-2241.
87. Biederman DM, Fischman AM, Titano JJ, et al. Tailoring the endovascular management of transplant renal artery stenosis. *Am J Transplant.* 2015;15(4):1039-1049.
88. Douis H, Shabir S, Lipkin G, Riley P. Drug-eluting stent insertion in the treatment of in-stent renal artery restenosis in three renal transplant recipients. *J Vasc Interv Radiol.* 2008;19(12):1757-1760.
89. deSouza NM, Reidy JF, Koffman CG. Arteriovenous fistulas complicating biopsy of renal allografts: treatment of bleeding with superselective embolization. *AJR Am J Roentgenol.* 1991;156(3):507-510.

90. Fossaceca R, Guzzardi G, Cerini P, et al. Management of postbiopsy arteriovenous fistulas in transplanted kidneys and effectiveness of endovascular treatment: a single-center experience. *Ann Vasc Surg.* 2014;28(2):452-456.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.